The U.S. National Institutes of Health launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe Covid-19.

Eli Lilly and Co. has partnered with Amgen Inc. to increase the supply of the Indianapolis-based company’s experimental Covid-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.

Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.

Seven U.S. states reported record one-day increases in Covid-19 cases so far in September even as the average daily number of new infections is falling nationally.

Eli Lilly and Co. said the company’s rheumatoid arthritis drug baricitinib shortened the recovery time for hospitalized Covid-19 patients also given Gilead Sciences Inc.’s antiviral remdesivir.

U.S. hospitals have turned down about a third of their allocated supplies of the Covid-19 drug remdesivir since July as need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed.

The National Institutes of Health launched two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating Covid-19 among adults.

A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.

Sanofi announced disappointing results from a Phase III study of intravenously dosed Kevzara (sarilumab) in which hospitalized Covid-19 patients failed to meet primary and secondary endpoints.

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against Covid-19.